Preventive Pharmacological Therapy and Risk of Recurrent Urinary Stone Disease

Area of Science:

• Nephrology
• Urology
• Pharmacology

Background:

• Urinary stone disease has a high recurrence rate, yet preventive therapies are underutilized due to limited evidence.
• This study investigates the effectiveness of pharmacological interventions in reducing recurrent urinary stone episodes.

Purpose of the Study:

• To evaluate the association between preventive pharmacological therapy and clinically significant urinary stone disease recurrence.
• To assess the impact of thiazide diuretics, alkali therapy, and uric acid-lowering medications on stone recurrence.

Main Methods:

• Analysis of Veterans Health Administration data from 2012-2019.
• Inclusion of adults with an index urinary stone episode and specific urinary abnormalities (hypercalciuria, hypocitraturia, hyperuricosuria).
• Cox proportional hazards regression to determine the association between therapy and recurrence events (ED visits, hospitalizations, surgery).

Main Results:

• Preventive therapy was associated with a 19% lower risk of recurrent urinary stones within 12-36 months (HR, 0.81; P=0.0496).
• Effectiveness diminished in longer follow-up periods (12-48 and 12-60 months).
• Alkali therapy for hypocitraturia showed a significant 26% reduction in recurrence risk within 12-36 months (HR, 0.74; P=0.03).

Conclusions:

• Preventive pharmacological therapy is associated with reduced clinically significant recurrent urinary stone disease within 12-36 months.
• Alkali therapy for hypocitraturia demonstrated a significant association with lower recurrence risk.
• Findings support the use of preventive therapy, especially alkali therapy, for managing recurrent urinary stones.